Photo of Prof John Field

Prof John Field MA. PhD, BDS, FRCPath.

Professor of Molecular Oncology (Clinical) Molecular and Clinical Cancer Medicine

    Biography

    Personal Statement

    Professor John Field, PhD, FRCPath has a Personal Clinical Chair in Molecular Oncology at the University of Liverpool. He is a Visiting Professor at University College London, holds the post of Director of Research of the Roy Castle Lung Cancer Research Programme. He is the Chief Investigator for the UK Lung Cancer Screening Trial (UKLS). Previous Chair of the IASLC Screening Prevention & Early Detection Committee and he formed IASLC Strategic Screening Advisory Group. Member of the ILCCO Steering Committee He was presented with the IASLC Joseph Cullen Award at the WCLC 2011, in recognition of lifetime scientific achievements in lung cancer prevention research. He is Chair of the IASLC Strategic Screening Advisory Committee.

    He is the principle investigator of the Liverpool Lung Project, a molecular- epidemiological study into the early detection of lung cancer (~12,000 recruited), funded by the Roy Castle Lung Cancer Foundation. The UKLS and the LLP form part of the NCRI Lung Cancer portfolio. He is also a Partner in the FP7 CURELUNG and LCAOS projects and the NIH GWAS non-smokers and the Oncoarray studies. He is also heavily involved in the identification of molecular diagnostic markers in lung and head & neck cancers. His research funding has been provided mainly by the RCF, NWCRF, MRC, CRUK, EU, NIH and the HTA.

    Professor Field is the author of over 270 international (peer reviewed) papers in his area of expertise and has given more than 350 presentations at medical and scientific conferences around the world.

    Web page:
    https://www.liv.ac.uk/translational-medicine/staff/john-field/

    Personal Distinctions

    • Lung Cancer Screening (Invitation to Speak, 14th National Lung Cancer Symposium Amsterdam 2012)
    • IASLC Joseph Cullen Award (IASLC 2012)
    • 14th National Lung Cancer Symposium Amsterdam (Invitation to Speak, ATS-2012 International Conference San Francisco, USA 2012)
    • dentifying Epidemiological, Clinical and Molecular Markers of Lung Cancer Risk Lung (Invitation to Speak, CHEST-2012 Atlanta 2012)
    • NCI & European Lung Cancer Screening Trials (Invitation to Speak, Fifth Asia Pacific Perspectives in Lung Cancer-ASIA LUNG , Hong 2012)
    • Lung cancer CT Screening - IASLC Position Statement (Keynote Speech, IASLC 2011)
    • Advances in screening for non-small cell lung cancer. (Invitation to Speak, The Royal Marsden Hospital 2011)
    • Summary of potential screening issues outside clinical trials post NLST press release (Invitation to Speak, International workshop on lung cancer screening randomised trials: state of the art in Europe after the early stop on the 2011)
    • Lung Cancer CT Screening trials. (Invitation to Speak, AACR 2011)
    • UKLS (Invitation to Speak, International workshop on lung cancer screening randomised trials: state of the art in Europe after the early stop on the 2011)
    • The NEXUS between early detection research programmes and the identification of target genetic and e (Invitation to Speak, CURELUNG EU project. Barcelona 2011)
    • Lung cancer Screening (Invitation to Speak, BTOG 2011 Conference Dublin 2011)
    • Biomarker Development (Invitation to Speak, IASLC Biomarkers Workshop WCLC – Amsterdam 2011)
    • Progress in risk assessment and early lung cancer screening (Invitation to Speak, Spanish Cancer Research Society -Salamanca 2011)
    • Biomarkers in Lung Cancer (Invitation to Speak, IASLC CT Screening Workshop, Amsterdam 2011)
    • UKLS: The UK lung Cancer Screening Study. (Invitation to Speak, Mesothelioma meeting, Imperial War Museum Duxford, Cambridge 2011)
    • Liverpool Lung Project & UK Lung Cancer Screening Trial (Invitation to Speak, International Conference Screening Network Biomarkers Workshop Future Opportunity. 2010)
    • Risk assessment for Lung cancer CT Screening Trial (Invitation to Speak, Arizona State University, Tempe, Arizona 2010)
    • Biorepositories: Lessons learned the Liverpool Lung Project repository (Invitation to Speak, Arizona State University, Tempe, Arizona 2010)
    • Personalization for Early Diagnosis and Treatment: who is at high risk? (Invitation to Speak, Danish Lung cancer 2010)
    • The Liverpool Lung Project (Invitation to Speak, Cancer Imaging Department of the British Columbia Cancer Research Agency 2010)
    • Is there a role for lung cancer screening? (Invitation to Speak, BASO - The Association for Cancer Surgery 2010)
    • selection of the target population for CT screening based on the work of the Liverpool Lung Project (Invitation to Speak, NELSON SYMPOSIUM 2009)
    • UKLS - UK Lung Cancer Screening (Invitation to Speak, BTOG 2009)
    • Stratification of High Risk Individuals for Early Lung Cancer Detection Screening and Trials (Invitation to Speak, IASLC 2009)
    • Chair - Lung Cancer Epidemiology and Health Services (Invitation to Speak, IASLC 2009)
    • British Thoracic Oncology Group Annual Meeting - speaker (Invitation to Speak, British Thoracic Oncology Group 2008)
    • UK Lung Cancer Screening Trial (Invitation to Speak, IASLC 2008)
    • Identification of High Risk individuals in Primary Care (Invitation to Speak, Nottingham PCT 2008)
    • EU spiral CT Screening Trials Collaborative Position Statement: Intended Collaboration (Invitation to Speak, American Cancer Society 2008)
    • Overview of Screening for Lung Cancer (Invitation to Speak, Mick Peake 2008)
    • Director of the Roy Castle Lung Cancer Research Programme (Roy Castle Lung Cancer Foundation 2004)
    • Director of Research, Roy Castle International Centre for Lung Cancer (Roy Castle Lung Cancer Foundation 1997)
    • Chairman of the EU Early Lung Cancer Detection Group. (EU Early Lung Cancer Detection Group. 1996)
    • Visiting Professor in the Eastman Dental Institute (University College London, November 1996 1996)

    Administrative Roles

    • Head of the Academic Unit of Maxillofacial Surgery, School of Dentistry (2001-2006)
    • Committees
    • Dental School Research Committee (2002 - 2006),
    • Dental Dean's Advisory Committee (2004-2006)
    • Faculty of Medicine Research Committee (2003-2006)
    • Academic Committee- Senate Reprsenative (2004-2006)
    • Academic Committee Standards Sub Committe (2004-2006)
    • Academic Committee Budget Committee (2004-2006)
    • School of Cancer Studies Exec Committee (2006- 2010 )
    • School of Cancer Studies Research Committee (2006- 2010)
    • School of Cancer Studies Admin Committee (2006- 2010)

    Untitled Document